Loading...
Market
TIGIT widely accepted as target for lung cancer treatment in clinical guidelines by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Updates to clinical guidelines from major oncology societies
Story
iTeos and GSK Show Promising Anti-TIGIT Results in Lung Cancer Study at ESMO 2024
Sep 14, 2024, 06:32 AM
iTeos Therapeutics and GSK have announced promising results from their mid-stage GALAXIES Lung-201 study, which investigates the combination of Belrestotug and Dostarlimab in first-line, PD-L1 high non-small cell lung cancer patients. The study, presented at the European Society for Medical Oncology (ESMO) 2024 conference, showed a clinically meaningful objective response rate at every dose level in a follow-up interim analysis. This development has renewed cautious optimism around anti-TIGIT immunotherapy drugs, which have faced setbacks in the past. The positive response rates suggest that TIGIT could be a viable target for lung cancer treatment.
View original story
Similar markets
Novocure • 25%
AstraZeneca • 25%
Chinese Biotech Firms • 25%
Other • 25%
Summit Therapeutics' ivonescimab • 25%
Merck's Keytruda • 25%
Roche's Tecentriq • 25%
Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Roche • 25%
AstraZeneca • 25%
Other • 25%
Merck & Co. • 25%
AstraZeneca • 25%
Roche • 25%
Other • 25%
Optune Lua with PD-1/PD-L1 inhibitors • 25%
Sunvozertinib • 25%
Durvalumab with chemotherapy • 25%
Other • 25%
Yes • 50%
No • 50%
Johnson & Johnson • 25%
Pfizer • 25%
AstraZeneca • 25%
Roche • 25%
